Teens With T1D, Obesity Reaped Benefits of GLP-1s, Case Studies Suggest
Two insulin-dependent adolescents with type 1 diabetes and obesity had metabolic improvements after starting a low-dose GLP-1 agent, a case series showed. One year after adding injectable semaglutide (Ozempic, Wegovy) to lifestyle intervention, a 17-year-old female with a 10-year history of type 1 diabetes lost 12 kg (26.5 lb) and reduced her body mass index…
